SlideShare a Scribd company logo
1 of 10
Download to read offline
ACCELERATING LIFE-CHANGING
BREAKTHROUGHS TO CURE, TREAT
AND PREVENT TYPE 1 DIABETES AND
ITS COMPLICATIONS
CONFIDENTIAL
A NEW STRATEGIC PLAN:
Effective August 30, 2015
A RESTRUCTURED ORGANIZATION:
Improved efficiency and productivity with lower costs
INCREASE IN LEADERSHIP GIVING:
Dedicated infrastructure to support high-level giving
LAUNCH JDRF THERAPEUTIC VENTURES:
New venture philanthropy approach with donors as active partners
SCALE LEVERAGE OF PUBLIC AND CORPORATE CAPITAL:
Use JDRF Therapeutic Ventures to exploit a proven strength
2
How We Get There
CONFIDENTIAL
ico
THE OPPORTUNITY
Changing the Course of T1D
PROGRAM THERAPEUTIC GOAL SHORT-TERM (5-7 YEAR) DELIVERABLES
ARTIFICIAL
PANCREAS
Fully-automated system combining continuous glucose
monitor and pump with algorithms to maintain near-normal
glucose levels with minimal user effort
Patient access and reimbursement of predictive low-
glucose suspend and treat-to-range systems; develop, test
and commercialize cell phone controlled, integrated seven-
day micro-patch pump/CGM
ENCAPSULATION
Restoration of insulin independence with replenishable
encapsulated beta cell product without immunosuppression
Clinical proof of concept of stem cell-derived islet & islet
progenitor transplants from multiple companies; multiple
companies within 5-10 years of product availability
GLUCOSE
RESPONSIVE
INSULIN
Change T1D treatment paradigm to once a day injection
resulting in near-normal glucose levels with minimal glucose
measurement, thereby reducing patient burden, short-term
risk, and long-term incidence of complications
Establish clinical proof of concept of at least one new GRI
technological approach; one or more companies in addition
to Merck on path to near- to mid-term commercialization
PREVENTION
Eliminate T1D as a threat to the next generation through
strategies and therapies to intercept and disrupt disease
onset and progression
Development of diabetes prevention vaccines and
therapies, including alteration in intestinal microbiome -
induced immunoregulation; clinical proof of concept with
commercialization in 7-10 years
BETA-CELL
RESTORATION
Return of biological insulin production through restoration
and regeneration of functional beta-cell mass combined with
autoimmunity mediation
Clinical validation of drug repurposing to reverse disease;
Development and proof of principle of gene edited human
stem cell derived islets resistant to immune attack
3CONFIDENTIAL
THE NEED
Changing the Course of T1D: $375-$625MM
PROGRAM SHORT-TERM (5-7 YEAR) DELIVERABLES INCREMENTAL FINANCIAL NEED
ARTIFICIAL
PANCREAS
Patient access and reimbursement of predictive low-glucose suspend and
treat-to-range systems; develop, test and commercialize cell phone
controlled, integrated seven-day micro-patch pump/CGM
$50-$100 MM
ENCAPSULATION
Clinical proof of concept of stem cell-derived islet & islet progenitor
transplants from multiple companies; multiple companies within 5-10 years
of product availability
$50-$75 MM
GLUCOSE
RESPONSIVE
INSULIN
Establish clinical proof of concept of at least one new GRI technological
approach; one or more companies in addition to Merck on path to near- to
mid-term commercialization
$25-$50 MM
PREVENTION
Development of diabetes prevention vaccines and therapies, including
alteration in intestinal microbiome -induced immunoregulation; clinical
proof of concept with commercialization in 7-10 years
$100-$150 MM
BETA-CELL
RESTORATION
Clinical validation of drug repurposing to reverse disease; Development and
proof of principle of gene edited human stem cell derived islets resistant to
immune attack
$150-$250 MM
4CONFIDENTIAL
5
MULTIPLYING THE IMPACT
JDRF Effectively Leverages Donor Funds
100.9 112.2 26.2 5.0
247.3 267.8
107.2
1,642.0
0
200
400
600
800
1,000
1,200
1,400
1,600
1,800
Industry Partners Foundations and Non-
Profit Partners
Foreign Government
Support
US Government
Support
Millions
Attracted Funding
JDRF Funding
2000 – 2022
2.5 2.4 4.1 Multiplier
CF FUND: In 1998, the CFF established a Therapeutics Development Program, a
pioneering partnership with the biotech community intended to expedite CF research
and the development of drugs to treat CF
VERTEX/KALYDECO: In return for royalty rights, the CFF invested $150 million in Vertex
Pharmaceuticals to develop the drug Kalydeco, effective in patients whose CF is caused
by a specific gene mutation. Following FDA approval of Kalydeco in 2012, CFF sold its
royalty rights at a profit and reinvested the funds in its research program
JOE O’DONNELL: Chairman of the ‘Milestone to a Cure’ major gifts campaign and
raised over $175 million for the Cystic Fibrosis Foundation. He currently chairs the
Milestones II campaign and plans to raise additional $75 million by the end of 2015
6
THE VEHICLE
Modeled After Cystic Fibrosis Foundation
CONFIDENTIAL
STRUCTURE: Single member LLC sponsoring a series of closed-end therapeutic funds;
maximum expense load of 10% over fund life.
FUNDING: Tax-deductible $500,000 contribution units; returns accrue to fund for
reinvestment or distribution to JDRF; Investments may include equity, royalty-based,
low-interest loans with warrant coverage, and/or pilot grants with shared IP or
commercial rights.
OPERATIONS: Separate entity for liability purposes; initially staffed by Steven Griffen,
M.D., JDRF VP, Translational Development & Jit Patel, JDRF VP, Research Business
Development; facilities, administration and finance contracted from JDRF.
GOVERNANCE: Five member JDRF Therapeutic Ventures board appointed by JDRF;
fund-specific oversight by scientific and device/bio-pharma experts, early stage
investors, and selected donors.
7
THE VEHICLE
JDRF Therapeutic Ventures, LLC
CONFIDENTIAL
 Leverage JDRF’s knowledge, network, staff and portfolio, knowledge to
identify most promising opportunities
 Create T1D-focused venture philanthropy funds to accelerate development,
commercialization and adoption of therapies
 Leverage capital through co-investments with universities, financial and
strategic investors
 Utilize and fund JDRF for regulatory, reimbursement, and adoption efforts
 Re-invest returns in therapeutic funds
JDRF THERAPEUTIC VENTURES
Change the Course of T1D
8CONFIDENTIAL
PARTICIPATION:
Advisory board seats; participation in fund investment strategy
COMMUNICATION:
Quarterly progress reports; annual donor briefing; additional access to
JDRF staff and researchers
NAMING OPPORTUNITIES:
Fund-specific opportunities for leadership gifts
JDRF THERAPEUTIC VENTURES
Donor Engagement & Recognition
9CONFIDENTIAL
THANK YOU
CONFIDENTIAL 10

More Related Content

More from sstrumello

Larry Soler Transcript-2004
Larry Soler Transcript-2004Larry Soler Transcript-2004
Larry Soler Transcript-2004sstrumello
 
Spinach and Artichoke Dip (Associated Press)
Spinach and Artichoke Dip (Associated Press)Spinach and Artichoke Dip (Associated Press)
Spinach and Artichoke Dip (Associated Press)sstrumello
 
Roche Social Media Summit June 2011
Roche Social Media Summit June 2011Roche Social Media Summit June 2011
Roche Social Media Summit June 2011sstrumello
 
IDF Presentation to 2011 Roche Social Media Summit
IDF Presentation to 2011 Roche Social Media SummitIDF Presentation to 2011 Roche Social Media Summit
IDF Presentation to 2011 Roche Social Media Summitsstrumello
 
The Glucose Getaway
The Glucose GetawayThe Glucose Getaway
The Glucose Getawaysstrumello
 
Emblem insulin formulary_change_2010
Emblem insulin formulary_change_2010Emblem insulin formulary_change_2010
Emblem insulin formulary_change_2010sstrumello
 
Biodel, Inc. Investor Presentation January 14, 2010
Biodel, Inc. Investor Presentation January 14, 2010Biodel, Inc. Investor Presentation January 14, 2010
Biodel, Inc. Investor Presentation January 14, 2010sstrumello
 
Pet contest winners
Pet contest winnersPet contest winners
Pet contest winnerssstrumello
 
JDRF Countdown July 2009
JDRF Countdown July 2009JDRF Countdown July 2009
JDRF Countdown July 2009sstrumello
 
Bentley (College) University Society Monthly Review
Bentley (College) University Society Monthly ReviewBentley (College) University Society Monthly Review
Bentley (College) University Society Monthly Reviewsstrumello
 
Most commercial insulin assays fail to detect recombinant insulin analogues
Most commercial insulin assays fail to detect recombinant insulin analoguesMost commercial insulin assays fail to detect recombinant insulin analogues
Most commercial insulin assays fail to detect recombinant insulin analoguessstrumello
 
Treatment of patients with new onset Type 1 diabetes with a single course of ...
Treatment of patients with new onset Type 1 diabetes with a single course of ...Treatment of patients with new onset Type 1 diabetes with a single course of ...
Treatment of patients with new onset Type 1 diabetes with a single course of ...sstrumello
 
Statement of Inger Mollerup, VP Novo Nordisk A/S for Congressional Hearings o...
Statement of Inger Mollerup, VP Novo Nordisk A/S for Congressional Hearings o...Statement of Inger Mollerup, VP Novo Nordisk A/S for Congressional Hearings o...
Statement of Inger Mollerup, VP Novo Nordisk A/S for Congressional Hearings o...sstrumello
 
Stanford University Case Study: Novo Nordisk
Stanford University Case Study: Novo NordiskStanford University Case Study: Novo Nordisk
Stanford University Case Study: Novo Nordisksstrumello
 
Could Generic Insulin Soon Hit the U.S. Market?
Could Generic Insulin Soon Hit the U.S. Market?Could Generic Insulin Soon Hit the U.S. Market?
Could Generic Insulin Soon Hit the U.S. Market?sstrumello
 
Mr. Hypo Is My Friend
Mr. Hypo Is My FriendMr. Hypo Is My Friend
Mr. Hypo Is My Friendsstrumello
 
Different Potencies of Biosynthetic Human and Purified Porcine Insulin
Different Potencies of Biosynthetic Human and Purified Porcine InsulinDifferent Potencies of Biosynthetic Human and Purified Porcine Insulin
Different Potencies of Biosynthetic Human and Purified Porcine Insulinsstrumello
 

More from sstrumello (17)

Larry Soler Transcript-2004
Larry Soler Transcript-2004Larry Soler Transcript-2004
Larry Soler Transcript-2004
 
Spinach and Artichoke Dip (Associated Press)
Spinach and Artichoke Dip (Associated Press)Spinach and Artichoke Dip (Associated Press)
Spinach and Artichoke Dip (Associated Press)
 
Roche Social Media Summit June 2011
Roche Social Media Summit June 2011Roche Social Media Summit June 2011
Roche Social Media Summit June 2011
 
IDF Presentation to 2011 Roche Social Media Summit
IDF Presentation to 2011 Roche Social Media SummitIDF Presentation to 2011 Roche Social Media Summit
IDF Presentation to 2011 Roche Social Media Summit
 
The Glucose Getaway
The Glucose GetawayThe Glucose Getaway
The Glucose Getaway
 
Emblem insulin formulary_change_2010
Emblem insulin formulary_change_2010Emblem insulin formulary_change_2010
Emblem insulin formulary_change_2010
 
Biodel, Inc. Investor Presentation January 14, 2010
Biodel, Inc. Investor Presentation January 14, 2010Biodel, Inc. Investor Presentation January 14, 2010
Biodel, Inc. Investor Presentation January 14, 2010
 
Pet contest winners
Pet contest winnersPet contest winners
Pet contest winners
 
JDRF Countdown July 2009
JDRF Countdown July 2009JDRF Countdown July 2009
JDRF Countdown July 2009
 
Bentley (College) University Society Monthly Review
Bentley (College) University Society Monthly ReviewBentley (College) University Society Monthly Review
Bentley (College) University Society Monthly Review
 
Most commercial insulin assays fail to detect recombinant insulin analogues
Most commercial insulin assays fail to detect recombinant insulin analoguesMost commercial insulin assays fail to detect recombinant insulin analogues
Most commercial insulin assays fail to detect recombinant insulin analogues
 
Treatment of patients with new onset Type 1 diabetes with a single course of ...
Treatment of patients with new onset Type 1 diabetes with a single course of ...Treatment of patients with new onset Type 1 diabetes with a single course of ...
Treatment of patients with new onset Type 1 diabetes with a single course of ...
 
Statement of Inger Mollerup, VP Novo Nordisk A/S for Congressional Hearings o...
Statement of Inger Mollerup, VP Novo Nordisk A/S for Congressional Hearings o...Statement of Inger Mollerup, VP Novo Nordisk A/S for Congressional Hearings o...
Statement of Inger Mollerup, VP Novo Nordisk A/S for Congressional Hearings o...
 
Stanford University Case Study: Novo Nordisk
Stanford University Case Study: Novo NordiskStanford University Case Study: Novo Nordisk
Stanford University Case Study: Novo Nordisk
 
Could Generic Insulin Soon Hit the U.S. Market?
Could Generic Insulin Soon Hit the U.S. Market?Could Generic Insulin Soon Hit the U.S. Market?
Could Generic Insulin Soon Hit the U.S. Market?
 
Mr. Hypo Is My Friend
Mr. Hypo Is My FriendMr. Hypo Is My Friend
Mr. Hypo Is My Friend
 
Different Potencies of Biosynthetic Human and Purified Porcine Insulin
Different Potencies of Biosynthetic Human and Purified Porcine InsulinDifferent Potencies of Biosynthetic Human and Purified Porcine Insulin
Different Potencies of Biosynthetic Human and Purified Porcine Insulin
 

Recently uploaded

clean rooms and its classification .pptx
clean rooms and its classification .pptxclean rooms and its classification .pptx
clean rooms and its classification .pptxushakiranmai4
 
Spinal cord Gross anatomy with Clinical Anatomy.pptx
Spinal cord Gross anatomy with Clinical Anatomy.pptxSpinal cord Gross anatomy with Clinical Anatomy.pptx
Spinal cord Gross anatomy with Clinical Anatomy.pptxsiddharthroy26587
 
Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......anupamdas2143
 
Thyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disordersThyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disordersSai Sailesh Kumar Goothy
 
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTIONANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTIONojaswinihemane
 
Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)Ahmad Thanin
 
Ten lessons learnt as anesthetist.pptx
Ten  lessons  learnt as anesthetist.pptxTen  lessons  learnt as anesthetist.pptx
Ten lessons learnt as anesthetist.pptxtusharchokshi1
 
TARGET DELINEATION IN RECTUM CANCER BY DR KANHU
TARGET DELINEATION IN RECTUM  CANCER BY DR KANHUTARGET DELINEATION IN RECTUM  CANCER BY DR KANHU
TARGET DELINEATION IN RECTUM CANCER BY DR KANHUKanhu Charan
 
HERPES SIMPLEX VIRUS 12032019 TUESDAY pptx
HERPES SIMPLEX VIRUS 12032019 TUESDAY  pptxHERPES SIMPLEX VIRUS 12032019 TUESDAY  pptx
HERPES SIMPLEX VIRUS 12032019 TUESDAY pptxPulkitMittal54
 
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptINTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptKavitha Krishnan
 
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdfSGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdfHongBiThi1
 
CELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCECELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCEShubhadip Ghosh
 
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALKLaryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALKQuick MedTalk
 
Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)pranavguleria2
 
ANATOMY OF CEREBELLUM With Clinical Anatomy.pptx
ANATOMY OF CEREBELLUM With Clinical Anatomy.pptxANATOMY OF CEREBELLUM With Clinical Anatomy.pptx
ANATOMY OF CEREBELLUM With Clinical Anatomy.pptxsiddharthroy26587
 
Substance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionSubstance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionZeinabEmad3
 
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptxCholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptxRajendra Dev Bhatt
 
bleeding disorders 1 Dr.Nannika Pradhan
bleeding disorders 1  Dr.Nannika Pradhanbleeding disorders 1  Dr.Nannika Pradhan
bleeding disorders 1 Dr.Nannika Pradhanthesalberry
 
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdfEMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdfMayuriGamit2
 
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptxANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptxsiddharthroy26587
 

Recently uploaded (20)

clean rooms and its classification .pptx
clean rooms and its classification .pptxclean rooms and its classification .pptx
clean rooms and its classification .pptx
 
Spinal cord Gross anatomy with Clinical Anatomy.pptx
Spinal cord Gross anatomy with Clinical Anatomy.pptxSpinal cord Gross anatomy with Clinical Anatomy.pptx
Spinal cord Gross anatomy with Clinical Anatomy.pptx
 
Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......
 
Thyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disordersThyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disorders
 
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTIONANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
ANTIPERSPIRANTS AND DEODORANTS : MECHANISM OF ACTION
 
Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)
 
Ten lessons learnt as anesthetist.pptx
Ten  lessons  learnt as anesthetist.pptxTen  lessons  learnt as anesthetist.pptx
Ten lessons learnt as anesthetist.pptx
 
TARGET DELINEATION IN RECTUM CANCER BY DR KANHU
TARGET DELINEATION IN RECTUM  CANCER BY DR KANHUTARGET DELINEATION IN RECTUM  CANCER BY DR KANHU
TARGET DELINEATION IN RECTUM CANCER BY DR KANHU
 
HERPES SIMPLEX VIRUS 12032019 TUESDAY pptx
HERPES SIMPLEX VIRUS 12032019 TUESDAY  pptxHERPES SIMPLEX VIRUS 12032019 TUESDAY  pptx
HERPES SIMPLEX VIRUS 12032019 TUESDAY pptx
 
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptINTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
 
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdfSGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
SGK BỆNH LÝ GOUT YHN hay lắm nha aaaa.pdf
 
CELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCECELL BLOCK PREPARATION AND ITS IMPORTANCE
CELL BLOCK PREPARATION AND ITS IMPORTANCE
 
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALKLaryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
 
Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)Histology of lymph node(lymph node histology)
Histology of lymph node(lymph node histology)
 
ANATOMY OF CEREBELLUM With Clinical Anatomy.pptx
ANATOMY OF CEREBELLUM With Clinical Anatomy.pptxANATOMY OF CEREBELLUM With Clinical Anatomy.pptx
ANATOMY OF CEREBELLUM With Clinical Anatomy.pptx
 
Substance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionSubstance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), Addiction
 
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptxCholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
 
bleeding disorders 1 Dr.Nannika Pradhan
bleeding disorders 1  Dr.Nannika Pradhanbleeding disorders 1  Dr.Nannika Pradhan
bleeding disorders 1 Dr.Nannika Pradhan
 
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdfEMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
EMBRYOLOGY AND FOETAL DEVELOPMENT-mayu.pdf
 
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptxANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
 

JDRF Therapeutic Ventures, LLC

  • 1. ACCELERATING LIFE-CHANGING BREAKTHROUGHS TO CURE, TREAT AND PREVENT TYPE 1 DIABETES AND ITS COMPLICATIONS CONFIDENTIAL
  • 2. A NEW STRATEGIC PLAN: Effective August 30, 2015 A RESTRUCTURED ORGANIZATION: Improved efficiency and productivity with lower costs INCREASE IN LEADERSHIP GIVING: Dedicated infrastructure to support high-level giving LAUNCH JDRF THERAPEUTIC VENTURES: New venture philanthropy approach with donors as active partners SCALE LEVERAGE OF PUBLIC AND CORPORATE CAPITAL: Use JDRF Therapeutic Ventures to exploit a proven strength 2 How We Get There CONFIDENTIAL
  • 3. ico THE OPPORTUNITY Changing the Course of T1D PROGRAM THERAPEUTIC GOAL SHORT-TERM (5-7 YEAR) DELIVERABLES ARTIFICIAL PANCREAS Fully-automated system combining continuous glucose monitor and pump with algorithms to maintain near-normal glucose levels with minimal user effort Patient access and reimbursement of predictive low- glucose suspend and treat-to-range systems; develop, test and commercialize cell phone controlled, integrated seven- day micro-patch pump/CGM ENCAPSULATION Restoration of insulin independence with replenishable encapsulated beta cell product without immunosuppression Clinical proof of concept of stem cell-derived islet & islet progenitor transplants from multiple companies; multiple companies within 5-10 years of product availability GLUCOSE RESPONSIVE INSULIN Change T1D treatment paradigm to once a day injection resulting in near-normal glucose levels with minimal glucose measurement, thereby reducing patient burden, short-term risk, and long-term incidence of complications Establish clinical proof of concept of at least one new GRI technological approach; one or more companies in addition to Merck on path to near- to mid-term commercialization PREVENTION Eliminate T1D as a threat to the next generation through strategies and therapies to intercept and disrupt disease onset and progression Development of diabetes prevention vaccines and therapies, including alteration in intestinal microbiome - induced immunoregulation; clinical proof of concept with commercialization in 7-10 years BETA-CELL RESTORATION Return of biological insulin production through restoration and regeneration of functional beta-cell mass combined with autoimmunity mediation Clinical validation of drug repurposing to reverse disease; Development and proof of principle of gene edited human stem cell derived islets resistant to immune attack 3CONFIDENTIAL
  • 4. THE NEED Changing the Course of T1D: $375-$625MM PROGRAM SHORT-TERM (5-7 YEAR) DELIVERABLES INCREMENTAL FINANCIAL NEED ARTIFICIAL PANCREAS Patient access and reimbursement of predictive low-glucose suspend and treat-to-range systems; develop, test and commercialize cell phone controlled, integrated seven-day micro-patch pump/CGM $50-$100 MM ENCAPSULATION Clinical proof of concept of stem cell-derived islet & islet progenitor transplants from multiple companies; multiple companies within 5-10 years of product availability $50-$75 MM GLUCOSE RESPONSIVE INSULIN Establish clinical proof of concept of at least one new GRI technological approach; one or more companies in addition to Merck on path to near- to mid-term commercialization $25-$50 MM PREVENTION Development of diabetes prevention vaccines and therapies, including alteration in intestinal microbiome -induced immunoregulation; clinical proof of concept with commercialization in 7-10 years $100-$150 MM BETA-CELL RESTORATION Clinical validation of drug repurposing to reverse disease; Development and proof of principle of gene edited human stem cell derived islets resistant to immune attack $150-$250 MM 4CONFIDENTIAL
  • 5. 5 MULTIPLYING THE IMPACT JDRF Effectively Leverages Donor Funds 100.9 112.2 26.2 5.0 247.3 267.8 107.2 1,642.0 0 200 400 600 800 1,000 1,200 1,400 1,600 1,800 Industry Partners Foundations and Non- Profit Partners Foreign Government Support US Government Support Millions Attracted Funding JDRF Funding 2000 – 2022 2.5 2.4 4.1 Multiplier
  • 6. CF FUND: In 1998, the CFF established a Therapeutics Development Program, a pioneering partnership with the biotech community intended to expedite CF research and the development of drugs to treat CF VERTEX/KALYDECO: In return for royalty rights, the CFF invested $150 million in Vertex Pharmaceuticals to develop the drug Kalydeco, effective in patients whose CF is caused by a specific gene mutation. Following FDA approval of Kalydeco in 2012, CFF sold its royalty rights at a profit and reinvested the funds in its research program JOE O’DONNELL: Chairman of the ‘Milestone to a Cure’ major gifts campaign and raised over $175 million for the Cystic Fibrosis Foundation. He currently chairs the Milestones II campaign and plans to raise additional $75 million by the end of 2015 6 THE VEHICLE Modeled After Cystic Fibrosis Foundation CONFIDENTIAL
  • 7. STRUCTURE: Single member LLC sponsoring a series of closed-end therapeutic funds; maximum expense load of 10% over fund life. FUNDING: Tax-deductible $500,000 contribution units; returns accrue to fund for reinvestment or distribution to JDRF; Investments may include equity, royalty-based, low-interest loans with warrant coverage, and/or pilot grants with shared IP or commercial rights. OPERATIONS: Separate entity for liability purposes; initially staffed by Steven Griffen, M.D., JDRF VP, Translational Development & Jit Patel, JDRF VP, Research Business Development; facilities, administration and finance contracted from JDRF. GOVERNANCE: Five member JDRF Therapeutic Ventures board appointed by JDRF; fund-specific oversight by scientific and device/bio-pharma experts, early stage investors, and selected donors. 7 THE VEHICLE JDRF Therapeutic Ventures, LLC CONFIDENTIAL
  • 8.  Leverage JDRF’s knowledge, network, staff and portfolio, knowledge to identify most promising opportunities  Create T1D-focused venture philanthropy funds to accelerate development, commercialization and adoption of therapies  Leverage capital through co-investments with universities, financial and strategic investors  Utilize and fund JDRF for regulatory, reimbursement, and adoption efforts  Re-invest returns in therapeutic funds JDRF THERAPEUTIC VENTURES Change the Course of T1D 8CONFIDENTIAL
  • 9. PARTICIPATION: Advisory board seats; participation in fund investment strategy COMMUNICATION: Quarterly progress reports; annual donor briefing; additional access to JDRF staff and researchers NAMING OPPORTUNITIES: Fund-specific opportunities for leadership gifts JDRF THERAPEUTIC VENTURES Donor Engagement & Recognition 9CONFIDENTIAL